ICAM2 Specific Neutra™ Antibody Products

Are you struggling with prolonged drug development timelines or inconsistent results in targeting cell adhesion mechanisms? Creative Biolabs' ICAM2 specific Neutra™ antibody products leverage advanced recombinant engineering and high-affinity validation to enable precise detection, functional analysis, and therapeutic development for ICAM2-mediated pathologies.

Introduction to ICAM2

Intercellular adhesion molecule 2 (ICAM2), a transmembrane glycoprotein of the immunoglobulin superfamily, is critical for mediating leukocyte-endothelial interactions during inflammatory responses. It binds to lymphocyte function-associated antigen-1 (LFA-1) to regulate immune cell trafficking, angiogenesis, and immune surveillance. With a molecular weight of approximately 31 kDa, ICAM2 is constitutively expressed on endothelial cells, platelets, and lymphocytes, playing a pivotal role in both physiological and pathological processes.

• Structural Insights

ICAM2 comprises two extracellular immunoglobulin-like domains (D1 and D2), a single transmembrane helix, and a short cytoplasmic tail. The D1 domain directly interacts with LFA-1 through key residues, while the D2 domain stabilizes this interaction. Structural studies reveal that its compact, rigid conformation enables rapid binding to LFA-1 under shear stress, facilitating efficient leukocyte adhesion and transendothelial migration.

• Related Signaling Pathways

ICAM2-LFA-1 engagement activates downstream signaling cascades, including Rho GTPase-mediated cytoskeletal reorganization and NF-κB-driven pro-inflammatory cytokine production. These pathways amplify immune responses in chronic inflammation, atherosclerosis, and tumor microenvironments. Additionally, ICAM2 modulates VEGF signaling to influence angiogenesis, linking adhesion dynamics to vascular remodeling.

Fig.1 Role of ICAM2 in activating actin cytoskeleton-associated Rho GTPases.¹

• Disease Associations

Dysregulation of ICAM2 is implicated in inflammatory disorders (e.g., rheumatoid arthritis, inflammatory bowel disease), cardiovascular diseases (e.g., atherosclerosis), and cancer metastasis. Overexpression of ICAM2 in tumor-associated endothelium promotes immune cell infiltration and tumor progression, while its shedding into circulation serves as a biomarker for disease severity.

Applications of ICAM2 Neutralizing Antibodies

• Inflammatory Disease Research

Anti-ICAM2 antibodies elucidate mechanisms of leukocyte trafficking in chronic inflammation. By blocking adhesion, these antibodies reduce immune cell infiltration in preclinical models of arthritis and colitis, offering insights into novel anti-inflammatory therapies.

• Oncologic Therapeutic Development

In cancer, ICAM2-neutralizing antibodies disrupt tumor-endothelial interactions, limiting metastasis. They enhance the efficacy of immunotherapies by normalizing vascular permeability and improving T-cell infiltration into tumors.

• Cardiovascular Pathology Studies

Antibodies targeting ICAM2 mitigate endothelial activation in atherosclerosis, reducing plaque formation. They serve as tools to study endothelial dysfunction and test interventions for vascular diseases.

• Diagnostic Biomarker Validation

Quantifying soluble ICAM2 levels using ELISA-compatible antibodies aids in monitoring disease progression and therapeutic response in inflammatory and oncologic contexts.

Our Anti-ICAM2 Antibodies

Creative Biolabs' anti-ICAM2 antibodies are engineered for unparalleled specificity and versatility:

• High-Affinity Neutralizers: Block ICAM2-LFA-1 interactions to inhibit leukocyte recruitment in inflammatory models.
• Cross-Application Compatibility: Validated for flow cytometry (cell surface quantification), immunohistochemistry (tissue localization), and functional assays (leukocyte adhesion inhibition).
• Theranostic Potential: Support therapeutic antibody development for autoimmune diseases and cancer immunotherapy by targeting ICAM2-driven pathways.

Creative Biolabs offers ICAM2 specific Neutra™ antibody products that empower researchers to dissect adhesion biology and advance therapeutic innovation. With rigorously validated performance across functional and analytical platforms, our antibodies are indispensable for studies in immunology, oncology, and cardiovascular research.

Contact our scientific team today to explore custom solutions for your ICAM2-focused projects. Let's accelerate breakthroughs together.

REFERENCE

1. Guerra-Espinosa, Claudia, et al. "ICAMs in immunity, intercellular adhesion and communication." Cells 13.4 (2024): 339. Distributed under Open Access license CC BY 4.0. The image was modified by extracting and using only part of the original image. https://doi.org/10.3390/cells13040339